These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30958841)

  • 1. Attrition and delays before treatment initiation among patients with MDR-TB in China (2006-13): Magnitude and risk factors.
    Xu C; Li R; Shewade HD; Jeyashree K; Ruan Y; Zhang C; Wang L; Zhang H
    PLoS One; 2019; 14(4):e0214943. PubMed ID: 30958841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India.
    Shewade HD; Kokane AM; Singh AR; Verma M; Parmar M; Chauhan A; Chahar SS; Tiwari M; Khan SN; Gupta V; Tripathy JP; Nagar M; Singh SK; Mehra PK; Kumar AM
    BMC Health Serv Res; 2017 Apr; 17(1):249. PubMed ID: 28376789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low pre-diagnosis attrition but high pre-treatment attrition among patients with MDR-TB: An operational research from Chennai, India.
    Shewade HD; Nair D; Klinton JS; Parmar M; Lavanya J; Murali L; Gupta V; Tripathy JP; Swaminathan S; Kumar AMV
    J Epidemiol Glob Health; 2017 Dec; 7(4):227-233. PubMed ID: 29110862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh.
    Hossain ST; Isaakidis P; Sagili KD; Islam S; Islam MA; Shewade HD; Kamal SM; Husain A
    PLoS One; 2015; 10(6):e0129155. PubMed ID: 26110273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delay before drug susceptibility testing among patients with presumptive multidrug-resistant tuberculosis in Gujarat, India.
    Shewade HD; Shringarpure KS; Parmar M; Patel N; Kuriya S; Shihora S; Ninama N; Gosai N; Khokhariya R; Popat C; Thanki H; Modi B; Dave P; Baxi RK; Kumar AMV
    Trans R Soc Trop Med Hyg; 2018 Nov; 112(11):500-508. PubMed ID: 30137546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.
    Chen Y; Yuan Z; Shen X; Wu J; Wu Z; Xu B
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delay and attrition before treatment initiation among MDR-TB patients in five districts of Gujarat, India.
    Shewade HD; Shringarpure KS; Parmar M; Patel N; Kuriya S; Shihora S; Ninama N; Gosai N; Khokhariya R; Popat C; Thanki H; Modi B; Dave P; Baxi RK; Kumar AMV
    Public Health Action; 2018 Jun; 8(2):59-65. PubMed ID: 29946521
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment cascade for patients with multidrug- or rifampicin-resistant tuberculosis and associated factors with patient attrition in southeastern China: a retrospective cohort study.
    Chen B; Chen X; Ren Y; Peng Y; Wang F; Zhou L; Xu B
    J Infect Public Health; 2023 Jul; 16(7):1073-1080. PubMed ID: 37209611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provider reported barriers and solutions to improve testing among tuberculosis patients 'eligible for drug susceptibility test': A qualitative study from programmatic setting in India.
    Shewade HD; Kokane AM; Singh AR; Parmar M; Verma M; Desikan P; Khan SN; Kumar AMV
    PLoS One; 2018; 13(4):e0196162. PubMed ID: 29677210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.
    Gao J; Ma Y; Du J; Zhu G; Tan S; Fu Y; Ma L; Zhang L; Liu F; Hu D; Zhang Y; Li X; Li L; Li Q
    BMC Pulm Med; 2016 Feb; 16():26. PubMed ID: 26846562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
    Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
    BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for diagnosis and treatment delay among patients with multidrug-resistant tuberculosis in Hunan Province, China.
    Akalu TY; Clements ACA; Gebreyohannes EA; Xu Z; Bai L; Alene KA
    BMC Infect Dis; 2024 Feb; 24(1):159. PubMed ID: 38308252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome.
    Schaaf HS; Shean K; Donald PR
    Arch Dis Child; 2003 Dec; 88(12):1106-11. PubMed ID: 14670781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of tuberculosis, multidrug resistant tuberculosis and associated risk factors among smear negative presumptive pulmonary tuberculosis patients in Addis Ababa, Ethiopia.
    Sinshaw W; Kebede A; Bitew A; Tesfaye E; Tadesse M; Mehamed Z; Yenew B; Amare M; Dagne B; Diriba G; Alemu A; Getahun M; Fikadu D; Desta K; Tola HH
    BMC Infect Dis; 2019 Jul; 19(1):641. PubMed ID: 31324227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
    van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
    PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai.
    Chen Y; Yuan Z; Shen X; Wu J; Wu Z; Xu B
    Biomed Res Int; 2016; 2016():2628913. PubMed ID: 27652260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.